Paolo Ghia, MD, PhD, from the San Raffaele Scientific Institute, Milano, Italy discusses the prognostic value of complex karyotypes in chronic lymphocytic leukemia (CLL) and details the results from his team’s analysis on 4,000 samples from CLL patients to evaluate this prognostic value and what these karyotypes may predict. He also notes that these results cannot currently be used in clinical trials, although they will definitely be relevant in the future. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.